Lead allogeneic CAR T cell candidates exhibited cytokine release upon target exposure and displayed robust antitumor activity at low cell doses in vivo against both subcutaneous and intraperitoneal gastric cancer models….These efficacy and safety data suggest that allogeneic CLDN18.2 CARs may be an effective and clinically valuable treatment for patients with CLDN18.2-positive cancers.

...we describe the preclinical development of a novel therapeutic CLDN18.2 mAb and ADC….Complete regression of CDX tumors was observed in response to treatment with the CLDN18.2-ADC in three separate CLDN18.2 positive models (two pancreas, one gastric).

Here, we present the development of a new TAC T product targeting Claudin 18.2 (CLDN18.2) to treat gastric cancer....Intravenous administration of CLDN18.2-TAC T cells in mice carrying CLDN18.2-positive tumor xenografts led to a sustained anti-tumor response.